Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemdisiran in Healthy Volunteers and PNH
NCT02352493Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Apr 2016
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing ALN-CC5 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events at Day 280. Started Jan 2015; status: completed.
02
Drugs
cemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02352493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352493.